Explore Cell Therapy

Written by: National Marrow Donor Program/Be The Match
  • Summary

  • In Explore Cell Therapy, we dig into the latest cell and gene therapy research and best practices to help you advance care for patients with hematologic malignancies and disorders. You’ll hear interviews with well-known and up-and-coming physicians in the hematopoietic stem cell transplantation (HCT) and cell and gene therapy field. You’ll receive insights from the National Marrow Donor Program®/Be The Match® and our partners into what it takes to connect patients to the best available therapies. In season 2, we examine practice-changing research and hot topics in HCT and other cellular therapies. You’ll hear conversations with experts who specialize in HCT and at community hematology/oncology practices.
    Copyright 2021 All rights reserved.
    Show more Show less
Episodes
  • 11 - First-line BMT for Severe Aplastic Anemia, Pt. 2: Future Research and Care Coordination
    Jun 12 2024

    In this two-part episode, Amy DeZern, MD, MHS, with Johns Hopkins and Christin DeStefano, MD, with Uniformed Services University discuss bone marrow transplant as a first-line treatment for severe aplastic anemia, moving beyond the limitations of traditional immunosuppressive therapies for a curative treatment option.

    In Part II: Future Research and Care Coordination, experts underscore the critical importance of early referral and coordination between hematology/oncology and transplant centers while looking ahead at the exciting research and clinical trials yet to come.

    To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

    Show more Show less
    26 mins
  • 11 - First-line BMT for Severe Aplastic Anemia, Pt. 1: Outcomes and Equity
    Jun 11 2024

    In this two-part episode, Amy DeZern, MD, MHS, with Johns Hopkins and Christin DeStefano, MD, with Uniformed Services University discuss bone marrow transplant as a first-line treatment for severe aplastic anemia, moving beyond the limitations of traditional immunosuppressive therapies for a curative treatment option.

    In Part I: Outcomes and Equity, guests explore the benefits of haploidentical transplant, noting quicker recovery times and reduced complications compared to past methods. These advancements are particularly impactful for diverse populations, including military personnel.

    To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

    Show more Show less
    26 mins
  • 10 – Trends in HCT Equity, Access and Outcomes, Pt. 2: Personalization and Future Care
    Feb 29 2024

    In this two-part episode, Rachel Phelan, MD, MPH, with the Medical College of Wisconsin and Rafeek Yusuf, MD, PhD, with NMDP discuss the latest trends in access and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation according to their recent CIBMTR (Center for International Blood and Marrow Transplant Research) report.

    In Part II: Personalization and Future Care, guests highlight the importance of holistic, personalized care throughout the patient journey as we navigate the complexities of transplantation, advocate for precision medicine, and envision a future with even more inclusive and effective health care solutions.

    To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

    Show more Show less
    31 mins

What listeners say about Explore Cell Therapy

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.